Enorama Pharma AB Cash Flow-to-Debt Ratio
Enorama Pharma AB cash flow-to-debt ratio. Enorama Pharma AB (ERMA) has a Cash Flow-to-Debt Ratio of -0.26x as of June 2026, meaning its operating cash flow of Skr-14.97 Million could theoretically repay 0% of its total liabilities (Skr57.39 Million) in one year. Check Enorama Pharma AB (ERMA) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Enorama Pharma AB (2014–2025)
Cash flow-to-debt ratio of Enorama Pharma AB from 2014 to 2025. Historical debt coverage capacity for Enorama Pharma AB across 12 annual periods. Check Enorama Pharma AB total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Enorama Pharma AB Cash Flow-to-Debt Ratio by Year (2014–2025)
Enorama Pharma AB cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Enorama Pharma AB. For the full cash flow conversion analysis, see cash flow conversion of Enorama Pharma AB.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.87x | Skr-59.26 Million | Skr31.71 Million | ▲ +57.7% |
| 2024 | -4.41x | Skr-35.70 Million | Skr8.09 Million | ▼ -58.4% |
| 2023 | -2.79x | Skr-41.35 Million | Skr14.85 Million | ▼ -45.3% |
| 2022 | -1.92x | Skr-32.96 Million | Skr17.20 Million | ▼ -87.9% |
| 2021 | -1.02x | Skr-30.16 Million | Skr29.58 Million | ▼ -73.5% |
| 2020 | -0.59x | Skr-23.00 Million | Skr39.13 Million | ▲ +21.7% |
| 2019 | -0.75x | Skr-26.56 Million | Skr35.40 Million | ▼ -22.5% |
| 2018 | -0.61x | Skr-13.36 Million | Skr21.81 Million | ▲ +25.3% |
| 2017 | -0.82x | Skr-6.67 Million | Skr8.13 Million | ▲ +39.0% |
| 2016 | -1.34x | Skr-6.11 Million | Skr4.55 Million | ▼ -840.8% |
| 2015 | 0.18x | Skr480.00K | Skr2.64 Million | ▼ -38.9% |
| 2014 | 0.30x | Skr307.00K | Skr1.03 Million | — |